Merck KGaA licenses Glenmark diabetes drug

Germany's Merck KGaA has agreed to pay €25 million up front and up to €190 million in total to license Glenmark's DPP-4 inhibitor, GRC 8200, which is in Phase II trials. Glenmark retains marketing rights to India while Merck KGaA gains North America, Europe and Japan.

- see the press release on the pact

ALSO: As expected, Merck's Januvia has won FDA approval for type 2 diabetes. Analysts say that the drug, a new class of DPP-4 inhibitor, is likely to be a blockbuster along with Galvus, which is waiting on a decision from the FDA. Report